News (63)

Transcript : SYNLAB AG, Q1 2024 Earnings Call, May 08, 2024
SYNLAB delivers strong performance in Q1 2024 EQ
SYNLAB : Presentation on the Q1 Financial Report 2024 PU
DD: SYNLAB AG: Mathieu Floreani, sell EQ
SYNLAB : Agenda and convening of the general meeting PU
Transcript : SYNLAB AG, 2023 Earnings Call, Mar 25, 2024
SYNLAB delivers robust performance in FY 2023 EQ
Transcript : SYNLAB AG, Q3 2023 Earnings Call, Nov 08, 2023
Continued strong performance in the third quarter of 2023 EQ
SYNLAB AG publishes Joint Reasoned Statement on public acquisition offer by Cinven EQ
SYNLAB launches revolutionary bipolar disorder diagnostic test: myEDIT-B EQ
SYNLAB launches revolutionary bipolar disorder diagnostic test: myEDIT-B PU
SYNLAB AG: SYNLAB agrees to sell its veterinary diagnostics business to Mars EQ
Transcript : SYNLAB AG, H1 2023 Earnings Call, Aug 09, 2023
Declining covid tests and costs weigh on lab chain Synlab DP
Hardly any Covid tests left and rising costs weigh on laboratory services provider Synlab DP
SYNLAB AG: Continued strong performance in the second quarter of 2023 EQ
SYNLAB AG: SYNLAB invests in innovative Healthcare Centre in Florence EQ
Laboratory services provider Synlab divests Swiss business DP
SYNLAB AG: SYNLAB agrees to sell Swiss business to Sonic Healthcare EQ
Transcript : SYNLAB AG, Q1 2023 Earnings Call, May 10, 2023
Ebbing of the pandemic continues to benefit Synlab - share price rises nonetheless DP
SYNLAB AG: SYNLAB reports strong start to fiscal year 2023 EQ
Transcript : SYNLAB AG, Q4 2022 Earnings Call, Mar 16, 2023
SYNLAB AG: SYNLAB delivers robust underlying growth in FY 2022 EQ
Synlab extends contracts of group CEO Floreani and CFO Badarani DP
SYNLAB AG: Extension of the appointment of Mathieu Floreani as CEO and Sami Badarani as CFO EQ
Transcript : SYNLAB AG, 2022 Sales/ Trading Statement Call, Feb 07, 2023
Synlab expects lower sales and operating profit in 2023 DP
SYNLAB AG: SYNLAB reports trading update for FY 2022 and revises FY 2023 guidance from lower COVID-19 testing EQ
Transcript : SYNLAB AG, Q3 2022 Earnings Call, Nov 10, 2022
SYNLAB AG: SYNLAB reports strong underlying performance in 9M 2022, confirms 2022 guidance and releases 2023 guidance EQ
Transcript : SYNLAB AG, Q2 2022 Earnings Call, Aug 11, 2022
SYNLAB reports solid H1 2022 results and raises 2022 revenue guidance EQ
SYNLAB Seeks M&A CI
Transcript : SYNLAB AG - Analyst/Investor Day
Transcript : SYNLAB AG, Q1 2022 Earnings Call, May 12, 2022
SYNLAB reports a strong start to the fiscal year 2022 EQ
SYNLAB AG: SYNLAB Medical Congress: making healthcare future-proof with advanced diagnostics EQ
SYNLAB AG : Notification and public disclosure of transactions by persons EQ
Transcript : SYNLAB AG, Q4 2021 Earnings Call, Mar 16, 2022
SYNLAB AG: SYNLAB achieves record results in 2021 and exceeds all targets set at the IPO EQ
SYNLAB AG: SYNLAB joins the United Nations Global Compact initiative EQ
SYNLAB acquires Sistemas Genómicos of the Ascires Group in Spain, further strengthening its European leadership in genetics EQ
SYNLAB AG : Notification and public disclosure of transactions by persons EQ
12NextSee all

Insiders

Mathieu Floreani
Mathieu Floreani

Mr. Mathieu O. Floreani is a Chairman-Management Board & CEO at Synlab AG, a Co-Managing Director at LS Medizin Service GmbH, a Group Chief Executive Officer at SYNLAB International GmbH and a Co-Managing Director at Medizinisches Versorgungszentrum SYNLAB Leverkusen GmbH. He is on the Board of Directors at Synlab Diagnósticos Globales SA, ALcontrol Group Ltd., Labco UK Group Ltd. and SYNLAB Ltd. Mr. Floreani was previously employed as a President, Chief Executive Officer & Director by DHL Global Forwarding North America and a Managing Director by SYNLAB Medizinisches Versorgungszentrum Stuttgart GmbH.


Picture Andrea Floreani
Andrea Floreani

Andrea Floreani currently works as a Marketing Director at SIAT Società Italiana Acciai Trafilati SpA.



Picture Patrick Floreani
Patrick Floreani

Mr. Patrick Floreani, CFA MBA, is a Managing Director & Chief Investment Officer at WealthBridge Investment Counsel, Inc. He is also primarily responsible for the equity portion of client portfolios.
Mr. Floreani was previously employed as a Chief Investment Officer by Société Générale (Canada) and a Partner & Portfolio Manager by Canadian Wealth Management Corp.
He is a graduate of the University of Alberta.
After graduating with a Bachelor of Science degree, He then obtained his Master of Business Administration degree, also from the University of Alberta.
He obtained his Chartered Financial Analyst charter in 1998.




Picture Martin E. Floreani
Martin E. Floreani

Martin E.
Floreani
is currently the President & Chief Executive Officer at French Transit LLC since 2017.
Previously, he worked as the Regional Marketing Manager at Merck & Co., Inc., Vice President-Global Strategy at Stiefel Laboratories, Inc., VP-International Sales & Market Development at Advanced Bio-Technologies, Inc., and Chief Marketing Officer & EVP-International at Enaltus LLC.
Mr. Floreani completed his undergraduate and MBA degrees from Miami University.


Picture Zaz Floreani
Zaz Floreani

Zaz Floreani is currently a Partner at Firstmile Ventures LLC.
Previously, Zaz held positions as Director-Business Development at AVP Management Services, Inc., Principal at Genesis Global Trading, Inc., and Principal at Next Coast Ventures LLC.
Zaz has an undergraduate degree from the University of California, Los Angeles, and graduate degrees, including an MBA, from The University of Texas at Austin and McCombs School of Business.


Picture Wayne Floreani
Wayne Floreani

Wayne Floreani currently works as a Director at The Canada-Africa Chamber of Business.


Picture Martin Floreani
Martin Floreani

Martin Floreani founded FloSports, Inc. in 2006 and held the titles of President, Chief Executive Officer & Director.
Mr. Floreani is also the founder of Rokfin, Inc.

No results for this search

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW